目前的应用和terlipressin的未来方向
Dorothy Liu1,2,3, Adam Testro1,2,3, Avik Majumdar1,2,3
1Victorian Liver Transplant Unit, Austin Health, Melbourne, Victoria, Australia.
Hepatology communications
|April 3, 2025
概括
特里普林素是一种血管压素模拟剂,可以有效地控制门口高血压出血和肝综合征-急性损伤. 持续输液显示安全性和疗效得到改善,在去补偿性肝硬化和移植桥梁疗法中出现新的用途.
科学领域:
- 肝病学和药理学 肝病学和药理学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 胃肠病学 胃肠病学
背景情况:
- 特里普林素是一种用于门高血压出血和肝综合征-急性损伤的血管压素模拟剂.
- 连续输注特里普林素显示出比玻尿酸剂量更高的安全性和有效性.
- 在肝病管理中,terlipressin的既定和新兴指示正在扩大.
研究的目的:
- 审查特利普林素的不良影响和安全策略.
- 探索特里普林素在去补偿性肝硬化,包括耐火性炎的新兴适应症.
- 为肝移植候选人提供使用长期连续terlipressin输液的门诊计划的数据.
主要方法:
- 对terlipressin的既定和新兴用途的文献综述.
- 分析安全数据和不良事件概况.
- 介绍了新型门诊连续输液计划的结果.
主要成果:
- 连续注入terlipressin提供了较高的安全性和疗效相比,玻尿酸剂的管理.
- 特里普林素在治疗不补偿性肝硬化症中耐火性炎方面显示出有前途.
- 门诊连续输液计划作为肝移植候选人的有效桥梁治疗.
结论:
- 特里普林素的使用,特别是通过连续输注,随着安全性状况的改善而不断发展.
- 新兴的适应症和新的施用策略正在扩大terlipressin在肝脏疾病中的治疗作用.
- 长期连续输液是治疗肝移植候选人的复杂疾病的可行选择.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
107
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
107
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
128
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
128
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
113
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
113
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
394
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
394
01:24Glucagon-like Receptor Agonists
276
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
276